Reducing academic misrepresentation in the dermatology residency application process: A need for better reporting of research output - 10/10/20
Funding sources: None. |
|
Disclosure: Dr Lio reports research grants/funding from the National Eczema Association, Regeneron/Sanofi Genzyme, and AbbVie; is on the speakers bureau for Regeneron/Sanofi Genzyme, Pfizer, and L'Oréal; reports consulting/serving on advisory boards for UCB, Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie, Kiniksa, Eli Lilly, Micreos (stock options), La Roche Posay/L'Oréal, Pierre-Fabre, Johnson & Johnson, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Franklin Bioscience/Altus Labs, Verrica, TopMD, Arbonne, Amyris, and Burt's Bees; and is a board member and scientific advisory committee member of the National Eczema Association. Authors Zhao and Tegtmeyer have no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
Vol 83 - N° 5
P. e367-e368 - novembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?